Pulmocide
Inhaled medicines for the treatment of viral and fungal infections of the respiratory tract
Total raised
€28M
€27,700,000
Funding rounds
1
Investors
6
distinct backers
Active since
2017-02
latest 2017-02
Funding by year
EUR raised per yearSignals
High confidenceRaise-next likelihood18
base rate 48% for Series B
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 rounds| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2017-03-01 | Series B | €28M | F Prime Capital,Johnson & Johnson,Johnson & Johnson Innovation,SR One,SV Life Sciences,Touchstone Innovations | View deal → |